Expertise in
11
conditions

Dr. Ira S. Winer

Oncology
Karmanos Cancer Center
4100 John R St, 
Detroit, MI 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Expertise in
11
conditions
Karmanos Cancer Center
4100 John R St, 
Detroit, MI 

Overview

Ira Winer is an Oncologist practicing medicine in Detroit, Michigan.

Dr. Winer is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Ovarian Cancer, Endometrial Cancer, Vulvar Cancer, Vaginectomy, and Hernia Surgery.

He is actively involved in clinical research, co-authoring 50 peer reviewed articles and participating in 13 clinical trials. Dr. Winer is currently accepting new patients.

Specialties

Oncology

Licenses

Obstetrics & Gynecology in MI

Hospital Affiliations

Henry Ford Health Hospital
Karmanos Cancer Center
Harper University Hospital
Beaumont Hospital Royal Oak

Languages Spoken

English
Hebrew

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
McLaren Health
  • HMO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Priority Health
  • HMO
  • POS
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Karmanos Cancer Center
4100 John R St, Detroit, MI 48201

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
Enrollment Status: Recruiting
Publish Date: August 07, 2026
Intervention Type: Other, Procedure
Study Phase: Not Applicable
Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin
Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2026
Intervention Type: Drug, Procedure
Study Phase: Phase 1
Phase 2 Study of M6620 (VX-970) in Combination With Gemcitabine Versus Gemcitabine Alone in Subjects With Platinum-Resistant Recurrent Ovarian or Primary Peritoneal Fallopian Tube Cancer
Phase 2 Study of M6620 (VX-970) in Combination With Gemcitabine Versus Gemcitabine Alone in Subjects With Platinum-Resistant Recurrent Ovarian or Primary Peritoneal Fallopian Tube Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 06, 2026
Intervention Type: Drug
Study Phase: Phase 2
Phase 1 Dose Escalation and Expansion Cohort of Carboplatin and Gemcitabine With or Without M6620 (VX-970) in First or Second Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer
Phase 1 Dose Escalation and Expansion Cohort of Carboplatin and Gemcitabine With or Without M6620 (VX-970) in First or Second Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Drug, Other
Study Drugs: Berzosertib, Carboplatin, Gemcitabine
Study Phase: Phase 1
Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination With Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vaginal Cancer
Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination With Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vaginal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Procedure, Drug, Radiation, Other
Study Drugs: Cisplatin, Triapine
Study Phase: Phase 1
A Phase II Study of the PARP Inhibitor Olaparib in Combination With the DNA Damaging Agent Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma
A Phase II Study of the PARP Inhibitor Olaparib in Combination With the DNA Damaging Agent Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Procedure, Drug
Study Drugs: Olaparib, Temozolomide
Study Phase: Phase 2
A Randomized Phase 2 Study of Bevacizumab and Either Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory Ovarian Cancer
A Randomized Phase 2 Study of Bevacizumab and Either Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 08, 2026
Intervention Type: Biological, Drug
Study Drugs: Anetumab ravtansine, Bevacizumab, Paclitaxel
Study Phase: Phase 2
A Phase 1, Open-Label, Dose Escalation and Expansion Study of TH1902 in Patients With Advanced Solid Tumors
A Phase 1, Open-Label, Dose Escalation and Expansion Study of TH1902 in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: April 15, 2025
Intervention Type: Drug
Study Drug: TH1902
Study Phase: Phase 1
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2023
Intervention Type: Drug
Study Drug: Upifitamab rilsodotin
Study Phase: Phase 1/Phase 2
ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Drug
Study Drugs: Chemotherapy, Rucaparib
Study Phase: Phase 3
View 9 Less Clinical Trials

50 Total Publications

Safety and feasibility of concomitant urogynecologic and gynecologic oncology surgical procedures.
Safety and feasibility of concomitant urogynecologic and gynecologic oncology surgical procedures.
Journal: Gynecologic oncology
Published: January 28, 2026
Similar Doctors
Expertise in
15
conditions
Expertise in
15
conditions
Referral may be required

Henry Ford Cancer-Detroit

2800 W Grand Blvd, 
Detroit, MI 
 (1.6 miles away)
888-777-4167
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Shirish Gadgeel is an Oncologist practicing medicine in Detroit, Michigan. Dr. Gadgeel is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Squamous Cell Lung Carcinoma, EGFR Positive Lung Cancer, and Tissue Biopsy. Dr. Gadgeel is currently accepting new patients.

Expertise in
14
conditions
Expertise in
14
conditions
Referral may be required

Karmanos Cancer Center

4100 John R St, 
Detroit, MI 
 (0.1 miles away)
313-576-8715
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Elisabeth Heath is an Oncologist practicing medicine in Detroit, Michigan. Dr. Heath is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Prostate Cancer, Renal Cell Carcinoma (RCC), Familial Prostate Cancer, Prostatectomy, and Nephrectomy. Dr. Heath is currently accepting new patients.

Expertise in
32
conditions
Dr. Rashmi Chugh
Oncology | Hematology | Internal Medicine
Expertise in
32
conditions
Dr. Rashmi Chugh
Oncology | Hematology | Internal Medicine
Referral may be required

Rogel Cancer Center

1500 E Medical Center Dr, Floor B1 Reception E, 
Ann Arbor, MI 
 (34.6 miles away)
734-647-8902
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rashmi Chugh is a Hematologist and an Oncologist practicing medicine in Ann Arbor, Michigan. Dr. Chugh is highly rated in 32 conditions, according to our data. Her clinical expertise encompasses Adult Soft Tissue Sarcoma, Epithelioid Sarcoma, Desmoid Tumor, and Ewing Sarcoma. Dr. Chugh is currently accepting new patients.

Frequently Asked Questions about Dr. Ira S. Winer

How do I make an appointment with Dr. Ira S. Winer?

You can book an appointment with Dr. Ira S. Winer by calling their office at 248-922-6650. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ira S. Winer a top-rated expert for Ovarian Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ira S. Winer is classified as an Elite expert for Ovarian Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ira S. Winer specialize in?

While Dr. Ira S. Winer is a Oncology, they have specific expertise in Ovarian Cancer, Endometrial Cancer, and Vulvar Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Ira S. Winer participate in research or clinical trials?

Yes. Dr. Ira S. Winer has published 50 articles and abstracts on conditions like Ovarian Cancer. You can view a list of Dr. Ira S. Winer's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Ira S. Winer accept my insurance?

Dr. Ira S. Winer accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 248-922-6650 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Winer's expertise for a condition
ConditionClose
View All 23 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile